



Yondelis[®] sales continue to expand despite adverse economic situation

- *Net oncology sales increased by 9.3% with respect to the third quarter of 2010.*
- *R&D expenditure rose by 9.3% year-on-year.*
- *Grupo Zeltia is among Spain's leading companies in terms of R&D expenditure as a percentage of revenues.*
- *The number of countries where Yondelis[®] has been approved continues to expand*

Madrid, 27 October 2011: Grupo Zeltia continued to expand sales of its anti-tumour drug, Yondelis[®], despite the unfavourable economic context. Net oncology sales grew by 9.3% with respect to the third quarter of 2010.

Group net revenues totalled 120 million euro in the first nine months of 2011, 0.6% more than in the same period of 2010.

Exports by the Consumer Chemical subsidiaries continued to increase with respect to 3Q10. However, domestic sales declined in recent months due to the crisis, which has particularly affected consumer spending and household product consumption.

Biopharmaceuticals accounted for 50.6% of the Grupo Zeltia's total revenues in the first nine months of 2011.

The company's R&D expenditure rose 9.3% year-on-year. Grupo Zeltia is one of Spain's leading companies in terms of R&D spending as a percentage of revenues, according to recently-published EU data.

With regard to 3Q11 results, Mr Luis Mora, CEO of PharmaMar said: "Sales of Yondelis[®] have improved notably year-on-year despite reimbursement issues in



some European countries arising from the current economic crisis. We are aware of the difficulties caused by factors outside the company. We are working diligently to resolve these issues and adapt our strategy to the new situation—in both the economy and the pharmaceutical industry—to the benefit of our shareholders.”

About Zeltia:

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer’s disease and other neurodegenerative diseases; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

For more information, contact Zeltia at +34 91 444 4500

This note is also available in the "News" section of Zeltia's website (www.zeltia.com) and the "Pressroom" section of Noscira's website (www.noscira.com)